For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. CRISPR THERAPTC (CRSP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CRSP and the rest of the Medical group's stocks.
CRISPR THERAPTC is one of 763 individual stocks in the Medical sector. Collectively, these companies sit at #11 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRSP's full-year earnings has moved 8.35% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CRSP has moved about 197.87% on a year-to-date basis. In comparison, Medical companies have returned an average of -0.81%. This means that CRISPR THERAPTC is performing better than its sector in terms of year-to-date returns.
Breaking things down more, CRSP is a member of the Medical - Biomedical and Genetics industry, which includes 282 individual companies and currently sits at #157 in the Zacks Industry Rank. This group has lost an average of 6.47% so far this year, so CRSP is performing better in this area.
Investors with an interest in Medical stocks should continue to track CRSP. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. CRISPR THERAPTC (CRSP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CRSP and the rest of the Medical group's stocks.
CRISPR THERAPTC is one of 763 individual stocks in the Medical sector. Collectively, these companies sit at #11 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRSP's full-year earnings has moved 8.35% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CRSP has moved about 197.87% on a year-to-date basis. In comparison, Medical companies have returned an average of -0.81%. This means that CRISPR THERAPTC is performing better than its sector in terms of year-to-date returns.
Breaking things down more, CRSP is a member of the Medical - Biomedical and Genetics industry, which includes 282 individual companies and currently sits at #157 in the Zacks Industry Rank. This group has lost an average of 6.47% so far this year, so CRSP is performing better in this area.
Investors with an interest in Medical stocks should continue to track CRSP. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CRSP - FREE